Woolsey Pharmaceuticals, an innovative indications discovery company, is dedicated to transforming the treatment landscape for neurodegenerative diseases. With a proven team, strategy, and record, Woolsey is revolutionizing the way challenging diseases are addressed by repurposing existing drugs. Their focus lies on rare, neurodegenerative conditions such as Alzheimer's, Parkinson's, Huntington's, and more.

By repurposing drugs, Woolsey Pharmaceuticals offers a quicker route to regulatory approval, often at a fraction of the cost of developing new drugs from scratch. This accelerated approach can be life-changing for patients in dire need. Additionally, repurposed drugs carry a lower risk due to their known safety profiles.

One of Woolsey's flagship developments is BRAVYL®, an oral version of the approved fasudil drug. Fasudil, initially used to treat cerebral vasospasm, will now be explored for various indications. Currently, Woolsey has ongoing clinical trials for BRAVYL in patients with dementia, Amyotrophic Lateral Sclerosis (ALS), and Progressive Supranuclear Palsy (PSP) or Corticobasal Syndrome (CBS).

Discover more about Woolsey Pharmaceuticals' groundbreaking clinical trials and their commitment to improving lives by exploring their website